What Royalty Pharma Plc's (NASDAQ:RPRX) P/S Is Not Telling You
You may think that with a price-to-sales (or "P/S") ratio of 5.3x Royalty Pharma plc (NASDAQ:RPRX) is a stock to avoid completely, seeing as almost half of all the Pharmaceuticals companies in the Uni
Simply Wall StApr 25 09:40 ET
Press Release: PureTech Announces Annual Results -36-
For the years ended December 31, 2023 and 2022, the Group recognized the following changes in the value of subsidiary preferred shares:
Dow JonesApr 25 05:35 ET
Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Yahoo FinanceApr 20 08:29 ET
Express News | Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
Moomoo 24/7Apr 19 08:15 ET
Royalty Pharma To Go Ex-Dividend On May 16th, 2024 With 0.21 USD Dividend Per Share
April 18th - $Royalty Pharma(RPRX.US)$ is trading ex-dividend on May 16th, 2024. Shareholders of record on May 17th, 2024 will receive 0.21 USD dividend per share on June 14th, 2024. The ex-divide
moomoo NewsApr 17 19:40 ET
Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17
03:06 PM EDT, 04/17/2024 (MT Newswires) -- Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17
MT NewswiresApr 17 15:06 ET
Press Release: Royalty Pharma Declares Second Quarter 2024 Dividend
Royalty Pharma Declares Second Quarter 2024 Dividend NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend fo
Dow JonesApr 17 08:15 ET
Royalty Pharma Is Maintained at Buy by B of A Securities
Royalty Pharma Is Maintained at Buy by B of A Securities
Dow JonesApr 12 08:11 ET
Express News | Royalty Pharma : BofA Global Research Cuts Price Objective to $38 From $40
Moomoo 24/7Apr 12 06:16 ET
Looking Into Royalty Pharma's Recent Short Interest
Royalty Pharma's (NYSE:RPRX) short percent of float has fallen 3.91% since its last report. The company recently reported that it has 12.65 million shares sold short, which is 2.95% of all regular sha
BenzingaApr 4 11:15 ET
Form 144 | Royalty Pharma(RPRX.US) Insider Proposes to Sell 15.19 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 3, $Royalty Pharma(RPRX.US)$ Insider GG 1978 SICAF SIF S.A. - GG Strategic intends to sell 500K shares of its common stock on Apr 3, with a total market value of approximat
moomoo NewsApr 3 16:53 ET
Form 144 | Royalty Pharma(RPRX.US) Insider Proposes to Sell 30.37 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 3, $Royalty Pharma(RPRX.US)$ Insider MGG Strategic SICAF SIF S.A. - MGG Strategic intends to sell 1 million shares of its common stock on Apr 3, with a total market value o
moomoo NewsApr 3 16:53 ET
Royalty Pharma Plc's (NASDAQ:RPRX) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Yahoo FinanceMar 30 09:00 ET
Ford, Envista Holdings, and Alaska Air Are Among Additions to GS' Short Duration List
Seeking AlphaMar 28 13:49 ET
Has Royalty Pharma Plc (NASDAQ:RPRX) Stock's Recent Performance Got Anything to Do With Its Financial Health?
Most readers would already know that Royalty Pharma's (NASDAQ:RPRX) stock increased by 4.4% over the past three months. As most would know, long-term fundamentals have a strong correlation with mark
Simply Wall StMar 14 07:35 ET
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
Seeking AlphaMar 8 10:21 ET
Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at TD Cowen's 44th Annual Health Care Conference on March 5, 2024 at 10:30 a.m.
GlobeNewswireFeb 28 16:15 ET
There May Be Underlying Issues With The Quality Of Royalty Pharma's (NASDAQ:RPRX) Earnings
Royalty Pharma plc's (NASDAQ:RPRX) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details. NasdaqGS:RPRX Ea
Simply Wall StFeb 22 05:11 ET
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating
Royalty Pharma (RPRX) has an average rating of buy and price targets ranging from $37 to $60, according to analysts polled by Capital IQ. Price: 30.13, Change: +0.21, Percent Change: +0.70
MT NewswiresFeb 20 11:43 ET
Royalty Pharma Price Target Cut to $50.00/Share From $56.00 by Goldman Sachs
Royalty Pharma Price Target Cut to $50.00/Share From $56.00 by Goldman Sachs
Dow JonesFeb 20 10:46 ET
No Data
No Data